|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001554,
umls-concept:C0017480,
umls-concept:C0017601,
umls-concept:C0026336,
umls-concept:C0087111,
umls-concept:C0418981,
umls-concept:C0679083,
umls-concept:C1273870,
umls-concept:C1511972,
umls-concept:C1518527,
umls-concept:C1527178,
umls-concept:C1704686,
umls-concept:C1705938
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
1999-1-25
|
|
pubmed:abstractText |
Economic evaluation of new treatments in the field of glaucoma represents a challenge. In the absence of a clear epidemiological link between intra-ocular pressure (IOP) and disease progression to blindness, the economic impact of treatments that lower IOP on long-term outcome cannot be estimated. As an alternative, effectiveness may be expressed as the ability to control IOP over time, making it possible to estimate the cost-effectiveness of therapies. The objective of this study was to investigate treatment strategies for patients newly diagnosed with primary open-angle glaucoma (POAG) or ocular hypertension (OH) in Germany and to estimate the impact of new topical therapies on the total cost of treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0721-832X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
236
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
811-21
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9825256-Adrenergic beta-Antagonists,
pubmed-meshheading:9825256-Carbonic Anhydrase Inhibitors,
pubmed-meshheading:9825256-Cost-Benefit Analysis,
pubmed-meshheading:9825256-Drug Costs,
pubmed-meshheading:9825256-Drug Therapy, Combination,
pubmed-meshheading:9825256-Female,
pubmed-meshheading:9825256-Germany,
pubmed-meshheading:9825256-Glaucoma, Open-Angle,
pubmed-meshheading:9825256-Humans,
pubmed-meshheading:9825256-Insurance, Health, Reimbursement,
pubmed-meshheading:9825256-Intraocular Pressure,
pubmed-meshheading:9825256-Male,
pubmed-meshheading:9825256-Markov Chains,
pubmed-meshheading:9825256-Middle Aged,
pubmed-meshheading:9825256-Ocular Hypertension,
pubmed-meshheading:9825256-Prostaglandins F, Synthetic,
pubmed-meshheading:9825256-Retrospective Studies,
pubmed-meshheading:9825256-Sulfonamides,
pubmed-meshheading:9825256-Thiophenes,
pubmed-meshheading:9825256-Timolol
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany.
|
|
pubmed:affiliation |
Health Dynamics International Ltd., France. gisela.kobelt@easynet.fr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
